Kiniksa Pharmaceuticals International Plc [KNSA] stock is trading at $38.92, up 0.15%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KNSA shares have gain 2.13% over the last week, with a monthly amount glided 9.85%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] stock has seen the most recent analyst activity on September 29, 2025, when TD Cowen initiated its Buy rating and assigned the stock a price target of $60. Previously, Citigroup started tracking the stock with Buy rating on March 13, 2025, and set its price target to $40. On September 13, 2024, Jefferies initiated with a Buy rating and assigned a price target of $40 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $34 on May 03, 2024. BofA Securities reiterated its recommendation of a Buy and raised its price target to $40 on June 29, 2020. BofA/Merrill started tracking with a Buy rating for this stock on April 01, 2020, and assigned it a price target of $25. In a note dated March 11, 2019, Barclays initiated an Overweight rating and provided a target price of $26 on this stock.
Kiniksa Pharmaceuticals International Plc [KNSA] stock has fluctuated between $17.82 and $39.43 over the past year. Currently, Wall Street analysts expect the stock to reach $49 within the next 12 months. Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] shares were valued at $38.92 at the most recent close of the market. An investor can expect a potential return of 25.9% based on the average KNSA price forecast.
Analyzing the KNSA fundamentals
Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] reported sales of 529.33M for the trailing twelve months, which represents a growth of 44.34%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at 0.01%, Pretax Profit Margin comes in at 0.03%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.01 and Total Capital is 0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.47 points at the first support level, and at 38.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 39.38, and for the 2nd resistance point, it is at 39.84.
Ratios To Look Out For
For context, Kiniksa Pharmaceuticals International Plc’s Current Ratio is 3.57. Also, the Quick Ratio is 3.16, while the Cash Ratio stands at 1.63. Considering the valuation of this stock, the price to sales ratio is 5.45, the price to book ratio is 5.82 and price to earnings (TTM) ratio is 946.96.
Transactions by insiders
Recent insider trading involved Tessari Eben, CHIEF OPERATING OFFICER, that happened on Oct 14 ’25 when 12368.0 shares were sold. Officer, Tessari Eben completed a deal on Oct 14 ’25 to buy 12368.0 shares. Meanwhile, CHIEF OPERATING OFFICER Tessari Eben sold 42000.0 shares on Sep 29 ’25.
